Effect of probucol in hyperlipidemic patients during two years of administration.

Abstract

Probucol, a new cholesterol-lowering agent, was administered to ambulatory outpatients representing several classes of hyperlipoproteinemia (HL) for two years without dietary restriction. In 32 patients with Type II HL and 12 with Type IIB HL, statistically significant reduction in mean serum cholesterol levels occurred within two weeks and persisted… (More)

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.